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Systemic nitric oxide synthase inhibition improves coronary flow
reserve to adenosine in patients with significant stenoses
Abstract
We studied the impact of systemic infusion of the nitric oxide synthase (NOS) inhibitor
N(G)-monomethyl-L-arginine (L-NMMA) on coronary flow reserve (CFR) in patients with coronary
artery disease (CAD). We have previously demonstrated that CFR to adenosine was significantly
increased after systemic infusion of L-NMMA in normal volunteers but not in recently transplanted
denervated hearts. At baseline, myocardial blood flow (MBF; ml x min(-1) x g(-1)) was measured at rest
and during intravenous administration of adenosine (140 microg x kg(-1) x min(-1)) in 10 controls (47
+/- 5 yr) and 10 CAD patients (58 +/- 8 yr; P < 0.01 vs. controls) using positron emission tomography
and (15)O-labeled water. Both MBF measurements were repeated during intravenous infusion of 10
mg/kg L-NMMA. CFR was calculated as the ratio of MBF during adenosine to MBF at rest. CFR was
significantly higher in healthy volunteers than in CAD patients and increased significantly after
L-NMMA in controls (4.00 +/- 1.10 to 6.15 +/- 1.35; P < 0.0001) and in patients, both in territories
subtended by stenotic coronary arteries (>70% luminal diameter; 2.06 +/- 1.13 to 3.21 +/- 1.07; P <
0.01) and in remote segments (3.20 +/- 1.23 to 3.92 +/- 1.62; P < 0.05). In conclusion, CFR can be
significantly increased in CAD by a systemic infusion of L-NMMA. Similarly to our previous findings
in normal volunteers, this suggests that adenosine-induced hyperemia in CAD patients is constrained by
a mechanism that can be relieved by systemic NOS inhibition with L-NMMA.
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Am J Physiol Heart Circ Physiol 293: H2178–H2182, 2007. First
published July 27, 2007; doi:10.1152/ajpheart.01292.2006.—We
studied the impact of systemic infusion of the nitric oxide synthase
(NOS) inhibitor NG-monomethyl-L-arginine (L-NMMA) on coronary
flow reserve (CFR) in patients with coronary artery disease (CAD).
We have previously demonstrated that CFR to adenosine was signif-
icantly increased after systemic infusion of L-NMMA in normal
volunteers but not in recently transplanted denervated hearts. At
baseline, myocardial blood flow (MBF; ml min1 g1) was mea-
sured at rest and during intravenous administration of adenosine (140
g kg1 min1) in 10 controls (47  5 yr) and 10 CAD patients
(58  8 yr; P  0.01 vs. controls) using positron emission tomogra-
phy and 15O-labeled water. Both MBF measurements were repeated
during intravenous infusion of 10 mg/kg L-NMMA. CFR was calcu-
lated as the ratio of MBF during adenosine to MBF at rest. CFR was
significantly higher in healthy volunteers than in CAD patients and
increased significantly after L-NMMA in controls (4.00  1.10 to
6.15 1.35; P 0.0001) and in patients, both in territories subtended
by stenotic coronary arteries (70% luminal diameter; 2.06 1.13 to
3.21  1.07; P  0.01) and in remote segments (3.20  1.23 to
3.92  1.62; P  0.05). In conclusion, CFR can be significantly
increased in CAD by a systemic infusion of L-NMMA. Similarly to
our previous findings in normal volunteers, this suggests that ade-
nosine-induced hyperemia in CAD patients is constrained by a mech-
anism that can be relieved by systemic NOS inhibition with
L-NMMA.
coronary circulation; autonomic nervous system; ischemic heart dis-
ease; cardiac imaging; positron emission tomography
IT IS WELL ESTABLISHED THAT myocardial ischemia is a powerful
stimulus for vasodilatation of coronary resistive vessels. The
vasodilator response is reported to be near maximal for ische-
mic times of up to 15–20 s, while no further changes are
observed for longer ischemic times (16).
Experimental studies in animals have proven that intracoro-
nary or intravenous infusion of adenosine achieves a degree of
coronary vasodilatation comparable to that obtained after a
period of ischemia of 15–20 s. In normal humans, intravenous
infusion of 140 g/kg adenosine produces an increase in
myocardial blood flow (MBF) approximately fourfold above
the resting value with no further increase at higher adenosine
doses (12, 29).
In a recent study in normal volunteers (15), we demonstrated
that hyperemic MBF measured during the combined intravenous
infusion of adenosine (140 g/kg) and the nitric oxide synthase
(NOS) inhibitor NG-monomethyl-L-arginine (L-NMMA; 10 mg/
kg) was 53% higher than that during infusion of adenosine
alone. This effect seems to necessitate an intact cardiac inner-
vation, since no increase in MBF during the combined intra-
venous infusion of adenosine and L-NMMA was observed in
transplant recipients (6.5  2 mo after transplant) whose
hearts remain denervated for more than a year after the
grafting (1).
The purpose of the present study was to assess whether a
limitation of adenosine-induced hyperemia, similar to that
previously demonstrated in normal volunteers, is present in
patients with coronary artery disease (CAD).
METHODS
Study population. Ten patients (1 female) age 58  8 yr with
single-vessel CAD were studied. Mean total cholesterol was 6.1 0.8
mM. All patients described at least a 3-mo history of chronic stable
angina pectoris and had electrocardiographic (ECG) evidence of
myocardial ischemia, defined as 0.1 mV of horizontal or downslop-
ing ST segment depression, during exercise stress. All patients had a
significant stenosis (70% of luminal diameter) in a major coronary
branch. The coronary angiograms were analyzed by two independent,
experienced operators. The luminal diameter of the stenosed artery
and adjacent reference lumen was measured at end diastole in the
projection that demonstrated the most severe stenosis, and quantitative
analysis was performed using an automated edge-contour detection
system (Centricity QCA; General Electric Medical Systems, Milwau-
kee, WI). A significant stenosis was found in the left anterior descend-
ing artery in five patients, in the left circumflex in one patient, and in
the right coronary artery in four patients. All patients were receiving
treatment with aspirin and -blocking agents. However, in all patients
-blockers were withdrawn 48–72 h before the study day. Exclusion
criteria were a recent history (3 mo) of myocardial infarction or
unstable angina, an inability to undergo exercise tolerance testing, or
resting ECG patterns that would interfere with interpretation of ST
changes during exercise.
A group of 10 healthy male volunteers age 47 5 yr (P 0.01 vs.
patients) served as controls. The lipid profile was assessed in all
volunteers, and those with total cholesterol 6.4 mM (250 mg/100
ml) were excluded from the study. Their total cholesterol was 5.2 
1.0 mM. None of them had a history of cardiovascular disease,
smoking, or any other cardiovascular risk factor. None of the volun-
teers was receiving any form of drug treatment. Enrollment criteria
included normal heart rate, blood pressure, ECG, two-dimensional
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echocardiogram, and low clinical probability for CAD (6). Some of
the healthy volunteers’ data have been published previously (15).
In addition, all study subjects were carefully instructed to refrain
from intake of caffeine-containing beverages or food during the 24 h
preceding the study. A screening test for caffeine was performed in a
blood sample taken immediately before the positron emission tomog-
raphy (PET) scan from each subject. Caffeine was not detectable in
any of the blood samples.
PET measurement of MBF. MBF was measured using 15O-labeled
water (H215O) and an ECAT 931-08/12 15-slice PET scanner (CTI/
Siemens, Knoxville, TX). H215O (700–900 MBq) was injected as an
intravenous bolus over 20 s at an infusion rate of 10 ml/min, and
dynamic scanning was acquired over a period of 5.5 min (13, 14, 29).
The sinograms obtained were corrected for attenuation and recon-
structed on a MicroVax II computer (Digital Equipment, Marlboro,
MA) employing dedicated array processors and standard reconstruc-
tion algorithms. On factor images, generated by iterative reconstruc-
tion, regions of interest were drawn within the left atrium and on left
ventricular myocardium on consecutive image planes. These were
projected onto the dynamic H215O images to generate blood and tissue
time activity curves, which were fitted to a single-tissue compartment
tracer kinetic model to give values of MBF (ml min1 g1) (12, 14,
26, 28–30).
Coronary flow reserve (CFR) was calculated as the ratio of MBF
during adenosine to resting MBF. To account for the variability of
coronary driving pressure, we calculated resting and minimal (i.e.,
during adenosine infusion) coronary resistance (mmHg ml1 min g)
as the ratio of mean systemic arterial pressure to MBF (10, 26).
Study protocol. Under baseline conditions, MBF was measured
both at rest and during intravenous administration of adenosine (140
g kg1 min1), as previously reported (14, 28). Arterial blood
pressure was recorded by an automatic cuff sphygmomanometer at
1-min intervals, and the ECG was monitored continuously throughout
the procedure. A 12-lead ECG was recorded at baseline and every
minute during adenosine administration. Thereafter, repeat measure-
ments of MBF both at rest and during intravenous adenosine (140
g kg1 min1) were carried out following a 30-min intravenous
infusion of 10 mg/kg L-NMMA (Clinalfa, La¨ufelfingen, Switzerland)
dissolved in 50 ml of isotonic saline.
The study protocol was approved by the Research Ethics commit-
tees of Hammersmith Hospital. Radiation exposure was licensed by
the UK Administration of Radioactive Substances Advisory Commit-
tee. All patients gave informed and written consent before the study.
Statistical analysis. Data are means  SD. Statistical comparison
of hemodynamic data, MBF, CFR, and coronary resistance during the
different study conditions was carried out using analysis of variance
for repeated measurements and post hoc Fisher’s protected least
significant difference test. A P value 0.05 was considered signifi-
cant.
RESULTS
Baseline study. The main hemodynamic parameters in nor-
mal volunteers and patients during the different study phases
are reported in Table 1. No significant difference was detect-
able between the two groups except for a higher heart rate-
systolic pressure product (RPP) in CAD patients at rest. In both
groups, RPP increased significantly with adenosine.
In patients, resting MBF in territories subtended by a ste-
notic artery was not statistically different from MBF in normal
volunteers, whereas MBF in remote myocardium subtended by
a nonstenotic artery tended to be higher (Table 2 and Fig. 1).
During adenosine infusion, the MBF increase in normal vol-
unteers was greater than that observed in patients in territories
subtended by a stenotic artery, whereas it was comparable to
that in remote myocardium subtended by a nonstenotic artery
(Table 2 and Fig. 1). CFR was significantly higher in volunteers
than in CAD patients (P 0.01 vs. remote myocardium and P
0.001 vs. myocardium subtended by a stenotic artery) (see Table
2). Minimal coronary resistance (during intravenous adenosine)
was 28.5  9.9 mmHg ml1 min g in normal volunteers,
64.1  26.0 mmHg ml1 min g in territories subtended by a
stenotic artery (P 0.0005 vs. healthy volunteers), and 32.2
11.2 mmHg ml1 min g in remote myocardium [P  nonsig-
nificant (NS) vs. healthy volunteers and P  0.005 vs. stenotic
territories].
L-NMMA infusion. Mean arterial pressure both at rest and
during adenosine increased significantly after L-NMMA infusion,
whereas corresponding heart rates were reduced (Table 1). Rest-
ing MBF was substantially unchanged in normal volunteers
and patients both in territories subtended by a stenotic artery
and in remote myocardium (Table 2 and Fig. 1). During
adenosine infusion, MBF increased significantly compared
with the respective baseline data both in normal volunteers and
in patients. In the latter, there was a significant increase both in
territories subtended by stenotic arteries and in remote myo-
cardium. Similarly, CFR increased significantly in both groups
(Table 2). Minimal coronary resistance decreased to 17.4 3.1
mmHg ml1 min g in normal volunteers (P  0.0005 vs.
baseline) and to 47.1  18.8 mmHg ml1 min g in territories
subtended by a stenotic artery (P  0.05 vs. baseline and P 
0.0001 vs. normal volunteers) and tended to decrease in remote
myocardium (29.4  15.3 mmHg ml1 min g, P  NS vs.
baseline and P  0.01 vs. normal volunteers).
DISCUSSION
The main finding of the present study is that the systemic
infusion of L-NMMA in patients with CAD significantly in-
creases the MBF response to adenosine in territories subtended
by stenotic (70% luminal diameter) coronary arteries. The
results of the present study extend our previous observations in
healthy volunteers and demonstrate that the maximum MBF
Table 1. Hemodynamics
Group
Baseline L-NMMA
Rest Adenosine Rest Adenosine
MAP HR RPP MAP HR RPP MAP HR RPP MAP HR RPP
1 869 599 6,7141,239 909 9315b 11,5742,239b 957d 529d 6,5921,181 9011a 7813b,d 9,5961,800b,d
2 9510 6311 8,3081,957 9915 9417b 13,3063,572b 11313d 5911 9,5742,701 10713 8321b,c 13,0574,408a
P ns ns 0.05 ns ns ns ns ns 0.01 ns ns 0.05
Values are heart rate (HR; beats/min), mean arterial pressure (MAP; mmHg), and rate-pressure product (RPP; systolic blood pressure  HR) at baseline and
after NG-monomethyl-L-arginine (L-NMMA) infusion in controls (group 1) and coronary artery disease (CAD) patients (group 2). P values shown are for
between-group comparison; ns, no significant difference between groups. aP  0.05; bP  0.005 vs. rest. cP  0.05; dP  0.005 vs. respective baseline.
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response to adenosine in humans is constrained by what could
to be a neurally mediated vasoconstriction of resistance ves-
sels. This latter is relieved by systemic infusion of L-NMMA
potentially via central neuronal NOS (nNOS) inhibition, as
suggested by the lack of flow increase after L-NMMA observed
in transplant recipients that was demonstrated in our group’s
previous study (15).
The notion that the MBF response to adenosine and/or
dipyridamole does not represent the maximum flow achievable
in the coronary system has been previously demonstrated in
both animals and humans. In open-chest anesthetized dogs,
L’Abbate et al. (16) demonstrated that prolonged intracoronary
infusion of adenosine provoked a biphasic flow response: at
first, within 15–30 s, coronary flow increased to a level similar
to that observed during reactive hyperemia after a 30-s coro-
nary occlusion; subsequently, continuing the infusion led to
further coronary vasodilatation that within 20–45 min from the
start of the infusion reached a plateau at a value that was twice
as much as that observed during reactive hyperemia and
remained constant up to 2 h.
	-Adrenoceptor-mediated coronary vasoconstriction can
compete with local metabolic vasodilation, as has been shown
in a number of studies in dogs, limiting the coronary vascular
response during sympathetic activation, e.g., exercise (4, 7, 9,
19), norepinephrine infusion, or carotid sinus reflex (18). The
role of 	-adrenoceptor-mediated coronary vasoconstriction has
also been investigated during maximal vasodilation to over-
come the confounding influence of autoregulation. In two
different studies, during adenosine infusion, Vlahakes et al.
(27) found higher flow after phentolamine and lower flow after
phenylephrine, and Johannsen et al. (11) observed lower flow
during cardiac sympathetic nerve stimulation and following
infusion of phenylephrine or norepinephrine. However, al-
though sympathetic discharge to the heart has been shown to
result in both 	-adrenergic constriction in the upstream vessels
and -adrenoceptor-mediated dilation in the coronary micro-
circulation, the latter has been found to be the dominant effect
in pigs and dogs (24). This may not necessarily apply to
humans. In fact, in a study in normal human volunteers in
whom MBF was measured noninvasively by means of PET,
Lorenzoni et al. (17) showed that the MBF response to dipy-
ridamole was increased by
40% when the study was repeated
during pharmacological blockade of 	1-adrenoceptors.
Our data suggest that the reflex sympathetic activation elic-
ited following the systemic administration of vasodilators such
as adenosine and dipyridamole should result in a further fall in
minimal coronary resistance. The latter, however, is blunted by
an NO-modulated suppression of sympathetic outflow in the
Fig. 1. Linear graphs showing individual values of rest and hyperemic (Ado) myocardial blood flow (MBF) at baseline and after NG-monomethyl-L-arginine
(L-NMMA) infusion in controls and in patients with coronary artery disease (CAD) in remote segments and in segments subtended by a stenotic artery (stenosis).
Table 2. Myocardial blood flow and coronary flow reserve
Group
MBF, ml  min1  g1
CFR (Relative Values)Baseline L-NMMA
Rest Adenosine Rest Adenosine Baseline L-NMMA
Controls 0.880.13 3.480.99 0.880.12 5.260.65c 4.001.10 6.151.35c
CAD
Remote 1.060.22d 3.270.96 1.140.22d 4.341.59a 3.201.23 3.921.62a,e
Stenosis 0.960.36 1.860.94e 0.840.29 2.691.24a,e 2.061.13e 3.211.07b,e
P ns 0.0001 0.05 0.005 0.01 ns
Values are myocardial blood flow (MBF) at baseline and after adenosine infusion and coronary flow reserve (CFR) at baseline and after L-NMMA infusion
in controls and in territories subtended by a stenotic artery and in remote myocardium in CAD patients. P values shown are for within-group comparison (CAD).
aP  0.05; bP  0.01; cP  0.0001 vs. baseline. dP  0.05; eP  0.005 vs. controls.
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central nervous system, where neuronal NO modulates neuro-
transmitter release (20). This is in line with our previous study,
which showed that an increase in the standard adenosine
infusion rate of 140 g kg1 min1 (12) does not further
decrease coronary resistance, whereas systemic coinfusion of
adenosine with L-NMMA further decreased coronary resis-
tance in healthy volunteers (15).
In the present study, the increase in MBF was significant in
both ischemic and remote territories of CAD patients. Never-
theless, CFR remained significantly lower in remote segments
than in controls after L-NMMA. This is in line with previous
observations in CAD patients reporting an impaired hyperemic
response in remote territories supplied by an angiographically
normal coronary artery (5, 23).
It remains controversial whether inhibition of nNOS elicits
sympathoexcitatory effects (21) or not (8), since it may exert
opposing effects at different sites (22). The present results in
CAD patients indicate that when the vasodilator is adminis-
tered during systemic inhibition of NOS, this constraint is
removed and the overall effect is a further dilatation and a
higher hyperemic flow.
Limitations of the study. Although our observations support
the above suggestion that neurally mediated vasoconstriction is
relieved by systemic NOS inhibition with L-NMMA, this must
remain a hypothesis. Similarly, we cannot comment on a
possible involvement of a parasympathetic component. To
provide final proof, a future study would need to demonstrate,
first, that an 	-adrenergic blockade causes augmentation of
coronary flow rates during adenosine similar to that produced
by L-NMMA [which has been reported by Lorenzoni et al. (17)
as mentioned above], and second, that after L-NMMA admin-
istration, 	-adrenergic blockade would not further increase
MBF response to adenosine. This, however, was beyond the
scope of the present study.
An additional limitation may be that CAD patients were
older than controls, and this difference may potentially have
hampered the comparability of the two groups’ CFR, since the
latter has been shown to decrease after the age of 60 yr (25),
although mainly because of an increase in basal flow (3). By
contrast, maximal hyperemic response decreases only after the
age of 70 yr (2), which would be irrelevant to our study since
none of our patients was older than 68 yr. Furthermore, the
experimental design using every subject as his own control
before and after L-NMMA administration and comparing ste-
notic versus remote segments within each subject further
strengthens our results.
L-NMMA induced a significant increase in mean arterial
pressure, which could theoretically have contributed to the
increase in hyperemic response after L-NMMA. This, however,
was been ruled out in our group’s previous study, in which
phenylephrine was used to increase blood pressure but did not
affect hyperemic response and CFR (4).
In conclusion, the present study provides evidence that
adenosine-induced hyperemic flow response in CAD patients is
constrained, potentially by neurally mediated vasoconstriction,
and that this can be relieved by systemic NOS inhibition with
L-NMMA. Further studies are needed to ascertain whether the
findings of this investigation offer the possibility of devising
some new form of treatment to improve myocardial perfusion
in patients with chronic CAD.
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